It’s been more than four decades since a new drug for tuberculosis has been approved by the FDA. Although Janssen is igniting hope with bedaquiline, which has been given priority review by the FDA and is set to begin late-stage trials this fall, there is still a great need for new ways to prevent and […]
Tuberculosis, diabetes and lupus are among the diseases targeted by Aarden Pharmaceuticals, based in Indiana. The company's technology inhibits protein tyrosine phosphatases, a step which scientists have long believed will unlock new treatments for an array of ailments.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.